Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2023 | May 11, 2023 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001504167 | |
Entity Registrant Name | Timber Pharmaceuticals, Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2023 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-37411 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 59-3843182 | |
Entity Address, Address Line One | 3 Mountainview Road, Suite 100 | |
Entity Address, City or Town | Warren | |
Entity Address, State or Province | NJ | |
Entity Address, Postal Zip Code | 07059 | |
City Area Code | 908 | |
Local Phone Number | 636-7163 | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | TMBR | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 3,044,484 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
ASSETS | ||
Cash | $ 5,175,484 | $ 9,080,426 |
Prepaid research and development | 204,443 | 525,532 |
Other current assets | 116,162 | 207,171 |
Total current assets | 5,496,089 | 9,813,129 |
Deposits | 145,137 | 127,534 |
Property and equipment, net | 20,047 | 19,373 |
Right of use asset | 615,437 | 315,932 |
Total assets | 6,276,710 | 10,275,968 |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||
Preferred stock par value $0.001; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 0 | 0 |
Common stock, par value $0.001; 450,000,000 shares authorized; 3,007,635 shares issued and outstanding as of March 31, 2023, and 2,969,272 shares issued and outstanding as of December 31, 2022 | 148,392 | 148,354 |
Additional paid-in capital | 53,487,614 | 53,350,126 |
Accumulated deficit | (52,325,244) | (48,263,992) |
Total stockholders' equity | 1,310,762 | 5,234,488 |
Total liabilities and stockholders' equity | 6,276,710 | 10,275,968 |
Current liabilities | ||
Accounts payable | 1,014,289 | 1,350,793 |
Accrued expenses | 1,576,229 | 1,609,535 |
Lease liability, current portion | 327,266 | 331,152 |
Short-term milestone payable due to Patagonia Pharmaceuticals LLC | 1,750,000 | 1,750,000 |
Total current liabilities | 4,667,784 | 5,041,480 |
Lease liability | 298,164 | 0 |
Total liabilities | 4,965,948 | 5,041,480 |
Commitments and contingencies (Note 7) |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 450,000,000 | 450,000,000 |
Common stock, shares issued (in shares) | 3,007,635 | 2,969,272 |
Common stock, shares outstanding (in shares) | 3,007,635 | 2,969,272 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue | $ 0 | $ 83,177 |
Operating costs and expenses | ||
Research and development | 2,365,751 | 1,518,959 |
Selling, general and administrative | 1,634,679 | 1,702,395 |
Total operating expenses | 4,000,430 | 3,221,354 |
Loss from operations | (4,000,430) | (3,138,177) |
Other income (expense) | ||
Interest expense | (62,977) | (54,252) |
Other income | 0 | 75,000 |
Forgiveness of PPP loan | 0 | 37,772 |
Gain on foreign currency exchange | 2,155 | 6,262 |
Total other income (expense) | (60,822) | 64,783 |
Net loss and comprehensive loss | (4,061,252) | (3,073,394) |
Net loss attributable to common stockholders | $ (4,061,252) | $ (3,073,394) |
Basic and diluted net loss per share attributable to common stockholders (in dollars per share) | $ (1.32) | $ (2.41) |
Basic and diluted weighted average number of shares outstanding (in shares) | 3,077,993 | 1,272,754 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) | Preferred Stock [Member] Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2021 | 0 | 1,272,383 | |||
Balance at Dec. 31, 2021 | $ 0 | $ 63,619 | $ 42,087,719 | $ (28,884,542) | $ 13,266,796 |
Stock-based compensation | 0 | 0 | 368,282 | 0 | 368,282 |
Net Income (Loss) Attributable to Parent | $ 0 | $ 0 | 0 | (3,073,394) | (3,073,394) |
Exercise of VARs (in shares) | 0 | 1,194 | |||
Exercise of VARs | $ 0 | $ 597 | (5,379) | 0 | (4,782) |
Balance (in shares) at Mar. 31, 2022 | 0 | 1,273,577 | |||
Balance at Mar. 31, 2022 | $ 0 | $ 64,216 | 42,450,622 | (31,957,936) | 10,556,902 |
Balance (in shares) at Dec. 31, 2022 | 0 | 2,969,272 | |||
Balance at Dec. 31, 2022 | $ 0 | $ 148,354 | 53,350,126 | (48,263,992) | 5,234,488 |
Stock-based compensation (in shares) | 0 | 2,250 | |||
Stock-based compensation | $ 0 | $ 2 | 137,524 | 0 | 137,526 |
Exercise of TardiMed Warrants (in shares) | 0 | 36,113 | |||
Exercise of TardiMed Warrants | $ 0 | $ 36 | (36) | 0 | 0 |
Net Income (Loss) Attributable to Parent | $ 0 | $ 0 | 0 | (4,061,252) | (4,061,252) |
Balance (in shares) at Mar. 31, 2023 | 0 | 3,007,635 | |||
Balance at Mar. 31, 2023 | $ 0 | $ 148,392 | $ 53,487,614 | $ (52,325,244) | $ 1,310,762 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Cash flows from operating activities | ||
Net loss | $ (4,061,252) | $ (3,073,394) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation | 137,526 | 368,282 |
Amortization of right of use assets | 86,177 | 76,550 |
Depreciation | 1,287 | 787 |
Forgiveness of PPP loan | 0 | (37,772) |
Non-cash interest on redeemable preferred stock | 0 | 54,252 |
Changes in assets and liabilities: | ||
Prepaid research and development | 321,087 | 4,397 |
Other current assets | 91,011 | 94,614 |
Deposits | (17,603) | 0 |
Accounts payable | (336,506) | (134,538) |
Accrued expenses | (33,307) | (222,043) |
Lease liability | (91,401) | (75,882) |
Net cash used in operating activities | (3,902,981) | (2,944,747) |
Cash flows from investing activities | ||
Purchase of property and equipment | (1,961) | (3,519) |
Net cash used in investing activities | (1,961) | (3,519) |
Cash flows from financing activities | ||
Net cash provided by financing activities | 0 | 0 |
Net decrease in cash | (3,904,942) | (2,948,266) |
Cash, beginning of period | 9,080,426 | 16,808,539 |
Cash, end of period | 5,175,484 | 13,860,273 |
Non-cash investing and financing activities: | ||
Cashless exercise of VARs | $ 0 | $ 60 |
Note 1 - Organization and Descr
Note 1 - Organization and Description of Business Operations | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | Note 1. Timber Pharmaceuticals, Inc., formerly known as BioPharmX Corporation (together with its subsidiaries Timber Pharmaceuticals Australia Pty Ltd., BioPharmX Inc. and Timber Pharmaceuticals LLC, the “Company” or “Timber”) is incorporated under the laws of the state of Delaware. Timber was founded in 2019 no no On November 7, 2022, 50 5:00 November 8, 2022 ( “2022 2022 not 2022 These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes in Item 8 Financial Statements and Supplementary Data 10 December 31, 2022 Merger Agreement On May 18, 2020, January 28, 2020 March 24, 2020 April 27, 2020 1 12 “2020 In connection with the Merger, the 11.68 VARs of Timber Sub that were outstanding immediately prior to Merger became denoted and payable in 7,353 shares of common stock at the effective time of the Merger (the “Effective Time”). Further, the holder of the 1,819,289 preferred units of Timber Sub outstanding immediately prior to the Merger received 1,819 shares of the Series A preferred stock (the “Series A Preferred Stock”) at the Effective Time. As part of the Merger, the Company assumed 4,401 legacy BioPharmX warrants with a weighted average exercise price of $8,208.50 per share, and 1,957 legacy BioPharmX stock options with a weighted average exercise price of $2,290.50 per share. In connection with the Merger Agreement, BioPharmX entered into a Credit Agreement with Timber Sub, pursuant to which Timber Sub made a bridge loan to the Company (the “Bridge Loan”), in an aggregate amount of $2.25 million with $250,000 original issue discount. In connection with the Merger Agreement, on March 27, 2022, tenth In addition, pursuant to the terms of the Securities Purchase Agreement, the Company issued to the Investors, on May 22, 2020, Investor Warrants Series A Warrants The Series A Warrants have an exercise price of $58.00 per share, were exercisable upon issuance and will expire on the day following the later to occur of (i) June 2, 2025, no March 31, 2023 Pursuant to the Series A Warrants, the Company agreed not May 1, 2021. one not 90th not If the Company fails to issue to a holder of Series A Warrants the number of shares of common stock to which such holder is entitled upon such holder’s exercise of the Series A Warrants, then the Company shall be obligated to pay the holder on each day while such failure is continuing an amount equal to 1.5% of the market value of the undelivered shares determined using a trading price of common stock selected by the holder while the failure is continuing and if the holder purchases shares of common stock in connection with such failure (“Series A Buy-In Shares”), then the Company must, at the holder’s discretion, reimburse the holder for the cost of such Series A Buy-In Shares or deliver the owed shares and reimburse the holder for the difference between the price such holder paid for the Series A Buy-In Shares and the market price of such shares, measured at any time of the holder’s choosing while the delivery failure was continuing. Further, the Series A Warrants provide that, in the event that the Company does not may On November 19, 2020, one Series B Warrants The Series B Warrants had an exercise price of $0.05 per share, were exercisable upon issuance and were exercised in full on March 4, 2021. On November 19, 2020 one December 31, 2020, The number of shares underlying a holder’s Series B Warrants was calculated using the existing formula set forth in the Series B Warrants and was reached by dividing the initial purchase price paid by the holder under the Purchase Agreement by a “Reset Price”, equal to the arithmetic average of the five 5 nine not Bridge Warrants The Bridge Warrants were issued on May 22, 2020, five November 2021 August 2022 August 2022 March 31, 2023 December 31, 2022, The Bridge Warrants provide that if Timber issues or sells or in accordance with the terms of the Bridge Warrants, is deemed to have issued or sold any shares of common stock for a price per share lower than the exercise price then in effect subject to certain limited exceptions, then the exercise price of the Bridge Warrants shall be reduced to such lower price per share. Upon the consummation of a Fundamental Transaction by the Company, upon any exercise of a Bridge Warrant, the holder shall have the right to receive, for each share of common stock that would have been issuable upon such exercise immediately prior to the occurrence of a Fundamental Transaction, at the option of the holder (without regard to any limitation on the exercise of the Bridge Warrant), the number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Bridge Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation on the exercise of the Bridge Warrant). For purposes of any such exercise, the determination of the exercise price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Additionally, at the request of a holder of a Bridge Warrant delivered before the 90th not The Bridge Warrants also contain a “cashless exercise” feature that allows the holders to exercise the Bridge Warrants without making a cash payment in the event that there is no 13 November 2021 On November 2, 2021, “November 2021 November 9, 2021, November 2021 “November November 5, 2021, November 2021 August 2022 Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a November November November November 5, 2021. November five November March 31, 2023 December 31, 2022 August 2022 On March 1, 2022, June 30, 2022 ( On August 4, 2022, “August 2022 “August August August 2022 August August may August five August August 2022 August 8, 2022. none August 8, 2022, August March 31, 2023 August not In connection with the August 2022 August 4, 2022, August 2022 August 2022 August August 2022 August 2022 August August 2022 October 2022 On October 3, 2022, “October “October 1 1 1 two one October October October 3, 2022. The Company filed a prospectus supplement (the “Prospectus Supplement”) on October 3, 2022, 1 3 No.333 255743 May 11, 2021, May 11, 2021 In a concurrent private placement (the “Concurrent Private Placement Offering” and, together with the Registered Offering, the “October 2022 2 2 1 2 Each share of Series B Preferred Stock has a stated value of $0.001 per share. The Series B Preferred Stock had super voting rights on the approval of the 2022 30 no no no The Series 2 six 6 two one not, 2 2 2 not 1933, 4 2 506 As compensation to Wainwright, as the exclusive placement agent in connection with the Registered Offering, the Company paid Wainwright a cash fee of 6% of the aggregate gross proceeds raised in the Registered Offering and reimbursed Wainwright for legal fees and expenses up to $40,000, non-accountable expenses of $25,000 and $15,950 for clearing expenses. In connection with the October 2022 Special Meeting and 2022 On November 7, 2022, one one first “2022 one October 27, 2022, On November 7, 2022, 5:00 November 8, 2022, 2022 one 2022 887080208. As a result of the 2022 one 2022 2022 not 2022 No 2022 November 9, 2022. no 2022 Liquidity and Capital Resources The Company has no may March 31, 2023 three March 31, 2023 March 31, 2023 Going Concern The Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one 10 March 31, 2023 second 2023. March 31, 2023 not twelve 10 The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not may The Company’s future liquidity and capital funding requirements will depend on numerous factors, including: ● its ability to raise additional funds to finance its operations, including its ability to access financing that may ● the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates, including the timing, progress, costs and results of its Phase 3 001 ● the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities; ● the emergence and effect of competing or complementary products; ● its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may may ● the cost and timing of completion of commercial-scale manufacturing activities if any of its products are approved for commercial sale; ● the cost of establishing sales, marketing and distribution capabilities for its products in regions where it chooses to commercialize its products on its own; ● the initiation, progress, timing and results of the commercialization of its product candidates, if approved for commercial sale, if approved for commercial sale; ● its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; and, ● the terms and timing of any collaborative, licensing or other arrangements that it has or may The Company will need to raise substantial additional funds through one one no |
Note 2 - Significant Accounting
Note 2 - Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | Note 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 X The results for the unaudited condensed consolidated statement of operations are not December 31, 2023, not Effective at 5:00 November 8, 2022 1 2022 2022 Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the valuations of warrants, and equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not may Reclassifications Certain reclassifications have been made to the condensed consolidated financial statements of prior years to conform to the current year presentation. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 March 31, 2023 December 31, 2022, Property and Equipment Property and equipment are recorded at cost and depreciated over their estimated useful life on a straight-line basis as follows: Furniture - 7 years Computer Equipment - 3 years Research and Development Research and development costs, including in-process research and development acquired as part of an asset acquisition for which there is no Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third third third Fair Value Measurement The Company follows the accounting guidance in ASC 820 The accounting guidance requires fair value measurements be classified and disclosed in one three Level 1: Level 2: 1 Level 3: no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. As of March 31, 2023 December 31, 2022 Leases The Company accounts for its leases under the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 842, Leases 842” In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components as permitted under ASC 842. 12 Revenue Recognition The Company has not 2022 Warrants The Company estimates the fair value of certain common stock warrants using a Black-Scholes option pricing model, and the assumptions used in calculating the fair value of such warrants represented management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The fair value of common stock warrants has been recorded in equity as additional paid-in-capital. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Series A Preferred Stock Under Redemption The Series A Preferred Stock under redemption was subject to certain limitations under Delaware law. Each share of Series A Preferred Stock was convertible at any time at the holder’s option into a number of shares of common stock (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions as specified in the Certificate of Designations) at a conversion price $902.70. Each share of Series A Preferred Stock was redeemable for cash at the option of the holders, in whole or in part. On November 23, 2021, December 31, 2021 On July 27, 2022, Twenty percent of the TardiMed Warrant was immediately exercisable upon issuance. Beginning on September 30, 2022, may August 3, 2022, October 26, 2022, January 3, 2023, Pursuant to the Letter Agreement, TardiMed released and discharged the Company and its affiliates from any and all claims, rights, demands, actions, suits, causes of action, liabilities, obligations, damages and costs of any nature whatsoever that TardiMed has, had or may March 31, 2023 Loss Per Share Basic net income (loss) per share (“EPS”) of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. To calculate the basic EPS numerator, income available to common stockholders must be computed by deducting both the dividends declared in the period on preferred stock (whether or not not If there is a loss from continuing operations or a net loss, the amount of the loss shall be increased by those preferred dividends. The Series A Preferred Stock had cumulative dividends, whether or not 2021. No 2022 The basic and diluted net loss amounts are the same for the three March 31, 2023 2022 As a result of the 2022 The following is a reconciliation of the numerator and denominator of the diluted net income (loss) per share computations for the periods presented below: Three Months Ended March 31, 2023 2022 Basic and diluted loss per share: Net (loss) income $ (4,061,252 ) $ (3,073,394 ) Net (loss) income attributable to common stockholders $ (4,061,252 ) $ (3,073,394 ) Basic and diluted weighted average number of shares outstanding 3,077,993 1,272,754 Basic and Diluted net (loss) per share attributable to common stockholders $ (1.32 ) $ (2.41 ) Securities that could potentially dilute income per share in the future were not three March 31, 2023 2022 March 31, 2023 2022 Series A warrants 334,036 334,036 Bridge warrants 8,275 8,275 Value appreciation rights 4,546 4,546 Options to purchase common stock 89,632 53,153 Series A preferred stock (if converted) — 2,337 Legacy stock options 316 316 Legacy warrants 2,027 4,235 Warrants issued in the November 2021 Financing 539,063 539,063 Warrants issued in the August 2022 Financing 1,309,333 — Warrants issued with October 2022 Financing 520,000 — Restricted Stock Units 750 — 2,807,978 945,960 Income taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more-likely than not not not The Company’s policy is to account for income tax related interest and penalties in income tax expense in the accompanying consolidated statements of operations. The Company made no three March 31, 2023 2022 Recent accounting pronouncements The Company did adopt any new Accounting Standard Updates during the quarter ended March 31, 2023. |
Note 3 - Purchases of Assets
Note 3 - Purchases of Assets | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Asset Acquisition [Text Block] | Note 3. Acquisition of Intellectual Property Rights from Patagonia Pharmaceuticals LLC ( Patagonia ) On February 28, 2019, 001, 001, 001 Upon closing of the TMB- 001 one 001, first 3 first first June 2022, first June 30, 2022. December 31, 2022 not March 31, 2023 not On July 20, 2022, first 3 second 2022. first September 1, 2022, September 1, 2023. 001 first September 1, 2022. second three March 31, 2023 On June 26, 2019, 003, S03, 003 Upon closing of the TMB- 003 one 003, first one not no March 31, 2023 December 31, 2022 On January 12, 2021, 003. Acquisition and Termination of License from AFT Pharmaceuticals Limited ( AFT ) On July 5, 2019, 2 The development of Pascomer had been conducted pursuant to a written development plan, written by AFT and approved by the joint steering committee, which is reviewed on at least an annual basis. AFT agreed to perform clinical trials of Pascomer in the specified territory and perform all CMC (chemistry, manufacturing and controls) and related activities to support regulatory approval. The Company was responsible for all expenses incurred by AFT during the term of the AFT License Agreement and equally shared all costs and expenses with AFT, incurred by AFT for development and marketing work performed in furtherance of regulatory approval and commercialization worldwide, outside of the specified territory. The Company was entitled to receive 50% March 2021 December 31, 2021. Pursuant to the AFT License Agreement, the Company was obligated to reimburse AFT for previously spent development costs, subject to certain limitations, and to pay a one 2020. first 2b not December 31, 2021. December 31, 2022, July 25, 2022 no On April 4, 2022, 0.2% first six 6 not 3 may On July 22, 2022, no 002 120 July 25, 2022 ( 002 no Other The Company disbursed approximately $2.23 million for a prepaid CRO payment for the start of its Phase 3 001 April 2022. March 31, 2023 |
Note 4 - Accrued Expenses
Note 4 - Accrued Expenses | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 4. As of March 31, 2023 December 31, 2022 March 31, December 31, 2023 2022 Research and development $ 531,040 $ 436,128 Professional fees 249,510 192,108 Personnel expenses 217,501 680,181 Accrued interest on Patagonia milestone payable 182,842 119,865 Asset Retirement Obligation for former BioPharmX location 150,000 150,000 Franchise tax payable 163,408 — Other 81,928 31,253 Total $ 1,576,229 $ 1,609,535 |
Note 5 - Stockholder's Equity
Note 5 - Stockholder's Equity | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | Note 5. s Equity The Company entered into a Merger Agreement with BioPharmX and effective May 18, 2020, Note 1 2022 On November 7, 2022, 1 1 1 October 27, 2022, On November 7, 2022, 1 5:00 November 8, 2022. 2022 2022 November 9, 2022. 2022 1003 All shares of common stock, including common stock underlying warrants, stock options, restricted stock units, and VARs, as well as all conversion ratios, exercise prices, conversion prices and per share information in these consolidated financial statements give retroactive effect to the 2022 Common Stock On May 18, 2020, one Under the terms of the Amended Merger Agreement, the Company issued shares of common stock to the holders of common units. The 180 common units issued to TardiMed have been converted into 113,323 shares of common stock, and the 20 common units issued to Patagonia have been converted into 12,591 shares of common stock. On May 18, 2020, 1 4 On May 18, 2020, 1 On November 2, 2021, November 5, 2021. five Wainwright also exercised its over-allotment option, pursuant to the underwriting agreement, to purchase an additional 70,313 shares of common stock and 70,313 warrants to purchase common stock at the public offering price per share and per warrant less the underwriters’ discounts and commissions. After giving effect to the sale of 70,313 additional shares pursuant to the exercise of the option that closed on November 9, 2021, November 5, 2021. March 31, 2023 December 31, 2022, Series A Warrants The following is a summary of the Series A Warrants outstanding as of March 31, 2023 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 334,306 $ 58.00 2.4 — Outstanding and exercisable as of March 31, 2023 334,306 $ 58.00 2.2 $ — Bridge Warrants The following table summarizes the Company’s Bridge Warrants for the three March 31, 2023 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 8,275 $ 1.00 2.4 $ 6,206 Outstanding and exercisable as of March 31, 2023 8,275 $ 1.00 2.1 $ 5,793 November 2021 The warrants issued by the Company were recorded as equity and recognized at fair value which was approximately $8.1 million. The value of the warrants issued by the Company in connection with November 2021 November 2021 No November March 31, 2023 December 31, 2022 1 The following table summarizes the Company’s November three March 31, 2023 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 539,063 $ 35.00 3.8 $ — Outstanding and exercisable as of March 31, 2023 539,063 $ 35.00 3.6 $ — Redeemable Series A Preferred Stock In connection with the Merger, on May 18, 2020, Pursuant to the Certificate of Designations, the Company designated 2,500 shares of the Company’s previously undesignated preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have no eight December 31, 2021, On November 23, 2021, three March 31, 2023 three March 31, 2022. On July 27, 2022, Twenty percent of the TardiMed Warrant was immediately exercisable upon issuance. Beginning on September 30, 2022, may August 3, 2022, October 26, 2022, January 4, 2023, March 31, 2023, Pursuant to the Letter Agreement, TardiMed released and discharged the Company and its affiliates from any and all claims, rights, demands, actions, suits, causes of action, liabilities, obligations, damages and costs of any nature whatsoever that TardiMed has, had or may The following table summarizes the TardiMed Warrant for the three March 31, 2023 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic TardiMed Warrant Exercise Price Term (Years) Value Outstanding as of December 31, 2022 108,651 $ 0.0050 * $ 189,595 Exercised (36,216 ) $ 0.0050 * $ — Outstanding and exercisable as of March 31, 2023 72,435 $ 0.0050 * $ 122,777 * Options expire once fully exercised; until exercised there is no August 2022 On August 4, 2022, “August 2022 August August The warrants issued by the Company were recorded as equity and recognized at fair value which was approximately $4.9 million. The value of the warrants issued by the Company in connection with August 2022 August 2022 The following table summarizes the August three March 31, 2023 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 1,309,333 $ 6.00 4.9 $ 4,844,533 Outstanding and exercisable as of March 31, 2023 1,309,333 $ 6.00 4.4 $ — October 2022 On October 3, 2022, October “October 1 1 two one October October October 3, 2022. In the “Concurrent Private Placement Offering” the Company issued (i) Series 2 2 Each share of Series B Preferred Stock has a stated value of $0.001 per share. The Series B Preferred Stock had super voting rights on the approval of the 2022 30 no no The Series 2 six 6 two one not, 2 2 2 not 1933, 4 2 506 The following tables summarizes the October three March 31, 2023: Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding and exerciseable as of December 31, 2022 520,000 $ 5.50 2.5 $ 5,200 Outstanding and exercisable as of March 31, 2023 520,000 $ 5.50 2.5 $ — |
Note 6 - Equity-Based Compensat
Note 6 - Equity-Based Compensation | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | Note 6. On May 18, 2020, 2020 “2020 2020 2020 three ten April 20, 2021, 2020 July 1, 2021. 2020 first 2022, December 31, 2021. March 31, 2023 2020 March 31, 2023 Furthermore, the Company maintains its 2019 “2019 2019 may March 31, 2023 2019 During the three March 31, 2023 2022 Three Months Ended March 31, 2023 2022 General and administrative value appreciation right awards $ 3,301 $ (10,754 ) General and administrative stock options 97,357 335,779 Research and development stock options 29,143 43,257 General and administrative restricted stock units 7,725 — $ 137,526 $ 368,282 Value Appreciation Rights In 2019 2019 During the three March 31, 2023 2022, three March 31, 2023 three March 31, 2022 March 31, 2023 Weighted Average Weighted Remaining Average Total Intrinsic Contractual Life Number of Units Exercise Price Value (in years) Outstanding as of December 31, 2022 4,546 $ 0.50 $ 5,682 6.5 Outstanding as of March 31, 2023 4,546 $ 0.50 $ 5,455 6.3 Value appreciation right awards vested and exercisable at March 31, 2023 2,883 $ 0.50 $ 3,460 6.3 As of March 31, 2023 Stock Options The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies. Additionally, due to an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The mid-point between the weighted-average vesting term and the expiration date is used as the expected term under this method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is zero not No stock option grants were made during the three March 31, 2023 2022, The following is a summary of the options outstanding as of March 31, 2023 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Options Exercise Price Term (Years) Value Outstanding at December 31, 2022 89,632 $ 37.37 8.9 $ 306 Outstanding at March 31, 2023 89,632 $ 37.37 8.6 $ 216 Exercisable at March 31, 2023 27,462 $ 55.95 8.3 $ — As of March 31, 2023 As part of the Merger, the Company assumed the following legacy stock options and warrants: Weighted Shares Average Underlying Weighted Remaining Aggregate Options and Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Legacy BioPharmX options - December 31, 2022 316 $ 3,763.55 0.4 $ — Legacy BioPharmX options - March 31, 2023 316 $ 3,623.63 0.1 $ — Legacy BioPharmX warrants - December 31, 2022 2,027 $ 5,250.00 1.8 $ — Legacy BioPharmX warrants - March 31, 2023 2,027 $ 5,250.00 1.6 $ — Restricted Stock Units The Company issued no RSUs in the three March 31, 2023. March 31, 2023 Weighted Shares Average Underlying Remaining Aggregate Restricted Grant Date Contractual Intrinsic Stock Units Fair Value Term (Years) Value Outstanding at December 31, 2022 3,000 $ 15.35 0.2 $ — Vested and issued (2,250 ) $ 15.35 - — Unvested at March 31, 2023 750 $ 15.35 0.1 $ — |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 7. Leases On February 8, 2023, 3 February 28, 2028. thirty-seventh On March 10, 2021, 110 110 401, twenty-four March 31, 2023. three March 31, 2022 March 31, 2023 In connection with the Merger of BioPharmX, the Company acquired a lease and corresponding sublease for the BioPharmX facility in San Jose, California. The sublease is to be used for general office and research laboratory purposes, has an effective date of February 1, 2020, December 30, 2023. fourth 2022 three March 31, 2023 The components of lease expense were as follows: Three months ended Three Months Ended March 31, 2023 March 31, 2022 Operating leases: Operating lease cost $ 99,896 $ 99,142 Variable lease cost 23,954 18,425 Operating lease expense $ 123,850 $ 117,567 Lease income - sub lease — (106,761 ) Net rent expense $ 123,850 $ 10,806 Other information: Three months ended Three months ended March 31, 2023 March 31, 2022 Operating cash flows - operating leases $ 105,147 $ 98,448 Right-of-use assets obtained in exchange for operating lease liabilities $ 385,682 $ — Weighted-average remaining lease term – operating leases 3.3 1.6 Weighted-average discount rate – operating leases 14.1 % 14.2 % As of March 31, 2023 Operating Leases Remaining Months in Year Ending December 31, 2023 $ 327,266 Year Ended December 31, 2024 107,820 Year Ended December 31, 2025 110,461 Year Ended December 31, 2026 113,101 Year Ended December 31, 2027 115,742 Thereafter 19,364 Total $ 793,754 Less: present value discount (168,324 ) Operating lease liabilities $ 625,430 Litigation The Company is not From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may |
Note 8 - Related Party Transact
Note 8 - Related Party Transactions | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 8. Patagonia Patagonia is a private, family-owned company founded in 2013 February 28, 2019, June 26, 2019, 001 003 Note 3 March 31, 2023 December 31, 2022 TardiMed The former Chairman of the Board of the Company is a Managing Member of TardiMed. Our former Chief Operating Officer, Executive Vice President and Secretary is a partner at TardiMed. Our Chief Financial Officer, Treasurer, Secretary, and Executive Vice President of the Company was also a former partner of TardiMed. As of March 31, 2023 three March 31, 2023 2022, On March 4, 2022, March 4, 2022, |
Note 9 - Subsequent Events
Note 9 - Subsequent Events | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 9. The Company has evaluated its subsequent events from March 31, 2023 no TardiMed Warrant Exercise On April 2, 2023, April 30, 2023, Note 5 Stock Options Granted Pursuant to the 2020 On April 15, 2023, April 15, 2024, 2020 16 1934, 4. RSUs Granted Pursuant to the 2020 On April 15, 2023, 2020 first one 16 1934, 4. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 X The results for the unaudited condensed consolidated statement of operations are not December 31, 2023, not Effective at 5:00 November 8, 2022 1 2022 2022 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the valuations of warrants, and equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not may |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications Certain reclassifications have been made to the condensed consolidated financial statements of prior years to conform to the current year presentation. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 March 31, 2023 December 31, 2022, |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are recorded at cost and depreciated over their estimated useful life on a straight-line basis as follows: Furniture - 7 years Computer Equipment - 3 years |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Research and development costs, including in-process research and development acquired as part of an asset acquisition for which there is no |
Accrued Outsourcing Costs, Policy [Policy Text Block] | Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third third third |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurement The Company follows the accounting guidance in ASC 820 The accounting guidance requires fair value measurements be classified and disclosed in one three Level 1: Level 2: 1 Level 3: no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. As of March 31, 2023 December 31, 2022 |
Lessee, Leases [Policy Text Block] | Leases The Company accounts for its leases under the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 842, Leases 842” In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components as permitted under ASC 842. 12 |
Revenue [Policy Text Block] | Revenue Recognition The Company has not 2022 |
Warrants Policy [Policy Text Block] | Warrants The Company estimates the fair value of certain common stock warrants using a Black-Scholes option pricing model, and the assumptions used in calculating the fair value of such warrants represented management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The fair value of common stock warrants has been recorded in equity as additional paid-in-capital. |
Share-Based Payment Arrangement [Policy Text Block] | Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, |
Preferred Stock [Policy Text Block] | Series A Preferred Stock Under Redemption The Series A Preferred Stock under redemption was subject to certain limitations under Delaware law. Each share of Series A Preferred Stock was convertible at any time at the holder’s option into a number of shares of common stock (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions as specified in the Certificate of Designations) at a conversion price $902.70. Each share of Series A Preferred Stock was redeemable for cash at the option of the holders, in whole or in part. On November 23, 2021, December 31, 2021 On July 27, 2022, Twenty percent of the TardiMed Warrant was immediately exercisable upon issuance. Beginning on September 30, 2022, may August 3, 2022, October 26, 2022, January 3, 2023, Pursuant to the Letter Agreement, TardiMed released and discharged the Company and its affiliates from any and all claims, rights, demands, actions, suits, causes of action, liabilities, obligations, damages and costs of any nature whatsoever that TardiMed has, had or may March 31, 2023 |
Earnings Per Share, Policy [Policy Text Block] | Loss Per Share Basic net income (loss) per share (“EPS”) of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. To calculate the basic EPS numerator, income available to common stockholders must be computed by deducting both the dividends declared in the period on preferred stock (whether or not not If there is a loss from continuing operations or a net loss, the amount of the loss shall be increased by those preferred dividends. The Series A Preferred Stock had cumulative dividends, whether or not 2021. No 2022 The basic and diluted net loss amounts are the same for the three March 31, 2023 2022 As a result of the 2022 The following is a reconciliation of the numerator and denominator of the diluted net income (loss) per share computations for the periods presented below: Three Months Ended March 31, 2023 2022 Basic and diluted loss per share: Net (loss) income $ (4,061,252 ) $ (3,073,394 ) Net (loss) income attributable to common stockholders $ (4,061,252 ) $ (3,073,394 ) Basic and diluted weighted average number of shares outstanding 3,077,993 1,272,754 Basic and Diluted net (loss) per share attributable to common stockholders $ (1.32 ) $ (2.41 ) Securities that could potentially dilute income per share in the future were not three March 31, 2023 2022 March 31, 2023 2022 Series A warrants 334,036 334,036 Bridge warrants 8,275 8,275 Value appreciation rights 4,546 4,546 Options to purchase common stock 89,632 53,153 Series A preferred stock (if converted) — 2,337 Legacy stock options 316 316 Legacy warrants 2,027 4,235 Warrants issued in the November 2021 Financing 539,063 539,063 Warrants issued in the August 2022 Financing 1,309,333 — Warrants issued with October 2022 Financing 520,000 — Restricted Stock Units 750 — 2,807,978 945,960 |
Income Tax, Policy [Policy Text Block] | Income taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more-likely than not not not The Company’s policy is to account for income tax related interest and penalties in income tax expense in the accompanying consolidated statements of operations. The Company made no three March 31, 2023 2022 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent accounting pronouncements The Company did adopt any new Accounting Standard Updates during the quarter ended March 31, 2023. |
Note 2 - Significant Accounti_2
Note 2 - Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended March 31, 2023 2022 Basic and diluted loss per share: Net (loss) income $ (4,061,252 ) $ (3,073,394 ) Net (loss) income attributable to common stockholders $ (4,061,252 ) $ (3,073,394 ) Basic and diluted weighted average number of shares outstanding 3,077,993 1,272,754 Basic and Diluted net (loss) per share attributable to common stockholders $ (1.32 ) $ (2.41 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | March 31, 2023 2022 Series A warrants 334,036 334,036 Bridge warrants 8,275 8,275 Value appreciation rights 4,546 4,546 Options to purchase common stock 89,632 53,153 Series A preferred stock (if converted) — 2,337 Legacy stock options 316 316 Legacy warrants 2,027 4,235 Warrants issued in the November 2021 Financing 539,063 539,063 Warrants issued in the August 2022 Financing 1,309,333 — Warrants issued with October 2022 Financing 520,000 — Restricted Stock Units 750 — 2,807,978 945,960 |
Note 4 - Accrued Expenses (Tabl
Note 4 - Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | March 31, December 31, 2023 2022 Research and development $ 531,040 $ 436,128 Professional fees 249,510 192,108 Personnel expenses 217,501 680,181 Accrued interest on Patagonia milestone payable 182,842 119,865 Asset Retirement Obligation for former BioPharmX location 150,000 150,000 Franchise tax payable 163,408 — Other 81,928 31,253 Total $ 1,576,229 $ 1,609,535 |
Note 5 - Stockholder's Equity (
Note 5 - Stockholder's Equity (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 334,306 $ 58.00 2.4 — Outstanding and exercisable as of March 31, 2023 334,306 $ 58.00 2.2 $ — Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 8,275 $ 1.00 2.4 $ 6,206 Outstanding and exercisable as of March 31, 2023 8,275 $ 1.00 2.1 $ 5,793 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 539,063 $ 35.00 3.8 $ — Outstanding and exercisable as of March 31, 2023 539,063 $ 35.00 3.6 $ — Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic TardiMed Warrant Exercise Price Term (Years) Value Outstanding as of December 31, 2022 108,651 $ 0.0050 * $ 189,595 Exercised (36,216 ) $ 0.0050 * $ — Outstanding and exercisable as of March 31, 2023 72,435 $ 0.0050 * $ 122,777 Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding as of December 31, 2022 1,309,333 $ 6.00 4.9 $ 4,844,533 Outstanding and exercisable as of March 31, 2023 1,309,333 $ 6.00 4.4 $ — Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Outstanding and exerciseable as of December 31, 2022 520,000 $ 5.50 2.5 $ 5,200 Outstanding and exercisable as of March 31, 2023 520,000 $ 5.50 2.5 $ — |
Note 6 - Equity-Based Compens_2
Note 6 - Equity-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended March 31, 2023 2022 General and administrative value appreciation right awards $ 3,301 $ (10,754 ) General and administrative stock options 97,357 335,779 Research and development stock options 29,143 43,257 General and administrative restricted stock units 7,725 — $ 137,526 $ 368,282 |
Share-Based Payment Arrangement, Activity [Table Text Block] | Weighted Average Weighted Remaining Average Total Intrinsic Contractual Life Number of Units Exercise Price Value (in years) Outstanding as of December 31, 2022 4,546 $ 0.50 $ 5,682 6.5 Outstanding as of March 31, 2023 4,546 $ 0.50 $ 5,455 6.3 Value appreciation right awards vested and exercisable at March 31, 2023 2,883 $ 0.50 $ 3,460 6.3 |
Schedule of Stock Options Roll Forward [Table Text Block] | Weighted Average Shares Weighted Remaining Aggregate Underlying Average Contractual Intrinsic Options Exercise Price Term (Years) Value Outstanding at December 31, 2022 89,632 $ 37.37 8.9 $ 306 Outstanding at March 31, 2023 89,632 $ 37.37 8.6 $ 216 Exercisable at March 31, 2023 27,462 $ 55.95 8.3 $ — |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block] | Weighted Shares Average Underlying Weighted Remaining Aggregate Options and Average Contractual Intrinsic Warrants Exercise Price Term (Years) Value Legacy BioPharmX options - December 31, 2022 316 $ 3,763.55 0.4 $ — Legacy BioPharmX options - March 31, 2023 316 $ 3,623.63 0.1 $ — Legacy BioPharmX warrants - December 31, 2022 2,027 $ 5,250.00 1.8 $ — Legacy BioPharmX warrants - March 31, 2023 2,027 $ 5,250.00 1.6 $ — |
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | Weighted Shares Average Underlying Remaining Aggregate Restricted Grant Date Contractual Intrinsic Stock Units Fair Value Term (Years) Value Outstanding at December 31, 2022 3,000 $ 15.35 0.2 $ — Vested and issued (2,250 ) $ 15.35 - — Unvested at March 31, 2023 750 $ 15.35 0.1 $ — |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Three months ended Three Months Ended March 31, 2023 March 31, 2022 Operating leases: Operating lease cost $ 99,896 $ 99,142 Variable lease cost 23,954 18,425 Operating lease expense $ 123,850 $ 117,567 Lease income - sub lease — (106,761 ) Net rent expense $ 123,850 $ 10,806 |
Other Information Related to Leases [Table Text Block] | Three months ended Three months ended March 31, 2023 March 31, 2022 Operating cash flows - operating leases $ 105,147 $ 98,448 Right-of-use assets obtained in exchange for operating lease liabilities $ 385,682 $ — Weighted-average remaining lease term – operating leases 3.3 1.6 Weighted-average discount rate – operating leases 14.1 % 14.2 % |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | Operating Leases Remaining Months in Year Ending December 31, 2023 $ 327,266 Year Ended December 31, 2024 107,820 Year Ended December 31, 2025 110,461 Year Ended December 31, 2026 113,101 Year Ended December 31, 2027 115,742 Thereafter 19,364 Total $ 793,754 Less: present value discount (168,324 ) Operating lease liabilities $ 625,430 |
Note 1 - Organization and Des_2
Note 1 - Organization and Description of Business Operations (Details Textual) | 3 Months Ended | 12 Months Ended | |||||||||||||||||||
Nov. 08, 2022 USD ($) shares | Nov. 07, 2022 $ / shares | Oct. 27, 2022 | Oct. 03, 2022 USD ($) $ / shares shares | Aug. 08, 2022 shares | Aug. 04, 2022 USD ($) $ / shares shares | Mar. 27, 2022 USD ($) $ / shares shares | Nov. 09, 2021 USD ($) $ / shares shares | Nov. 05, 2021 $ / shares | Nov. 02, 2021 $ / shares shares | May 22, 2020 $ / shares shares | May 18, 2020 USD ($) $ / shares shares | Mar. 31, 2023 USD ($) $ / shares shares | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2020 shares | Jul. 27, 2022 $ / shares | Mar. 01, 2022 $ / shares | Mar. 04, 2021 $ / shares shares | Nov. 19, 2020 $ / shares shares | May 20, 2020 shares | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 1 | ||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||
Common Stock, Shares, Issued (in shares) | 148,571,994 | 3,007,635 | 2,969,272 | ||||||||||||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 2,971,439 | 27,347 | 3,007,635 | 2,969,272 | |||||||||||||||||
Common Stock, Shares Authorized (in shares) | 450,000,000 | 450,000,000 | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 931,667 | ||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |||||||||||||||||||
Retained Earnings (Accumulated Deficit) | $ | $ (52,325,244) | $ (48,263,992) | |||||||||||||||||||
Net Income (Loss) Attributable to Parent | $ | (4,061,252) | $ (3,073,394) | |||||||||||||||||||
Net Cash Provided by (Used in) Operating Activities | $ | (3,902,981) | $ (2,944,747) | |||||||||||||||||||
Cash and Cash Equivalents, at Carrying Value | $ | $ 5,175,484 | $ 9,080,426 | |||||||||||||||||||
Reverse Stock Split [Member] | |||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 50 | 50 | 12 | ||||||||||||||||||
October 2022 Offerings [Member] | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 260,000 | ||||||||||||||||||||
Proceeds From Issuance Of Common Stock Gross | $ | $ 1,300,000 | ||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 1,000,000 | ||||||||||||||||||||
October 2022 Offerings [Member] | Wainwright [Member] | |||||||||||||||||||||
Stock Issuance Cost, Percentage | 6% | ||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 40,000 | ||||||||||||||||||||
Payment of Non-accountable Expenses Relating to Common Stock Issuance | $ | 25,000 | ||||||||||||||||||||
Payment of Clearing Charges Relating to Common Stock Issuance | $ | $ 15,950 | ||||||||||||||||||||
Minimum [Member] | Reverse Stock Split [Member] | |||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 25 | ||||||||||||||||||||
Maximum [Member] | Reverse Stock Split [Member] | |||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 50 | ||||||||||||||||||||
Securities Purchase Agreement [Member] | |||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 6,900,000 | ||||||||||||||||||||
Underwriting Agreement [Member] | |||||||||||||||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 539,063 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 426,500 | ||||||||||||||||||||
Proceeds From Issuance Of Common Stock Gross | $ | $ 17,250,000 | ||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 15,800,000 | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 32 | ||||||||||||||||||||
Underwriting Agreement [Member] | Maximum [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 539,063 | ||||||||||||||||||||
Investor Warrants [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||
Aggregate Purchase Price For Issuance Of Warrants | $ | $ 25,000,000 | ||||||||||||||||||||
Series A Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 334,306 | 334,306 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 58 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 334,036 | 403,564 | |||||||||||||||||||
Percentage on Market Trading Price to be Paid for Undeliverable Shares | 1.50% | ||||||||||||||||||||
Series A Warrants [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 2.7953 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 167,695 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||
Series B Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.05 | $ 0.05 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 455,336 | 455,336 | |||||||||||||||||||
Class Of Warrant Or Right, Exercised (in shares) | 305,855 | ||||||||||||||||||||
Stock Issued During Period, Shares, Exercise of Warrants (in shares) | 305,700 | ||||||||||||||||||||
Series B Warrants [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.05 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 140,844 | ||||||||||||||||||||
Warrants Related To Bridge Notes [Member] | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 8,275 | 8,275 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1 | $ 111.81 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 8,275 | 8,275 | 8,275 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||
Class of Warrant or Right, Exercisable Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | ||||||||||||||||||||
Warrants Related To Bridge Notes [Member] | Minimum [Member] | |||||||||||||||||||||
Percentage of Exercise Price on Reset Price | 499% | ||||||||||||||||||||
Warrants Related To Bridge Notes [Member] | Maximum [Member] | |||||||||||||||||||||
Percentage of Exercise Price on Reset Price | 999% | ||||||||||||||||||||
Prefunded Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.005 | $ 0.005 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 401,667 | 42,250 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 6 | ||||||||||||||||||||
Prefunded Warrants [Member] | Underwriting Agreement [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 31.95 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercisable Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.05 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | ||||||||||||||||||||
November 2021 Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 539,063 | 539,063 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 35 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 539,063 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||
Class Of Warrant Or Right, Exercised (in shares) | 0 | 0 | |||||||||||||||||||
Class of Warrant or Right, Number of Warrants Exercised (in shares) | 0 | 0 | |||||||||||||||||||
November 2021 Warrants [Member] | Underwriting Agreement [Member] | |||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||
Class of Warrant or Right, Exercisable Price of Warrants or Rights (in dollars per share) | $ / shares | $ 35 | ||||||||||||||||||||
Class of Warrant or Right, Number of Warrants Exercised (in shares) | 0 | 0 | |||||||||||||||||||
Common Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,333,333 | 468,750 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 5.995 | ||||||||||||||||||||
August 2022 Common Stock Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,309,333 | 1,309,333 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,333,333 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||
Class Of Warrant Or Right, Exercised (in shares) | 24,000 | ||||||||||||||||||||
Series One Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 260,000 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years 6 months | ||||||||||||||||||||
Series One Warrants [Member] | October 2022 Offerings [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 260,000 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years 6 months | ||||||||||||||||||||
Series Two Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 260,000 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years 6 months | ||||||||||||||||||||
Series Two Warrants [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 260,000 | ||||||||||||||||||||
Series B Mirroring Preferred Stock [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 13,000 | ||||||||||||||||||||
Series B Mirroring Preferred Stock [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 13,000 | ||||||||||||||||||||
Series A Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 58 | ||||||||||||||||||||
Warrants Related To Bridge Notes [Member] | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 111.81 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 8,275 | ||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |||||||||||||||||||
Number of Votes Per Share | 10,000,000 | 10,000,000 | |||||||||||||||||||
Average Minimum Bid Price Per Share (in dollars per share) | $ / shares | $ 0.20 | $ 0.20 | |||||||||||||||||||
Stock Cancelled During Period, Shares (in shares) | 13,000 | ||||||||||||||||||||
Consideration from Cancel of Stock | $ | $ 0 | ||||||||||||||||||||
Value Appreciation Rights [Member] | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 4,546 | 4,546 | |||||||||||||||||||
Timber Pharmaceuticals Limited Liability Company [Member] | Merger Agreement With Timber And Merger Sub [Member] | |||||||||||||||||||||
Number of Common Stock Issued for Value Appreciation Rights (in shares) | 7,353 | ||||||||||||||||||||
Preferred Units, Outstanding (in shares) | 1,819,289 | ||||||||||||||||||||
Timber Pharmaceuticals Limited Liability Company [Member] | Merger Agreement With Timber And Merger Sub [Member] | Bridge Loan [Member] | |||||||||||||||||||||
Long-Term Debt, Gross | $ | $ 2,250,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ | $ 250,000 | ||||||||||||||||||||
Timber Pharmaceuticals Limited Liability Company [Member] | Merger Agreement With Timber And Merger Sub [Member] | Legacy Bio Pharm Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 4,401 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 8,208.50 | ||||||||||||||||||||
Timber Pharmaceuticals Limited Liability Company [Member] | Merger Agreement With Timber And Merger Sub [Member] | Series A Warrants [Member] | |||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Units (in shares) | 1,819 | ||||||||||||||||||||
Timber Pharmaceuticals Limited Liability Company [Member] | Value Appreciation Rights [Member] | Merger Agreement With Timber And Merger Sub [Member] | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 11.68 | ||||||||||||||||||||
Timber Pharmaceuticals Limited Liability Company [Member] | Legacy Bio Pharm Options [Member] | Merger Agreement With Timber And Merger Sub [Member] | |||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 1,957 | ||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 2,290.50 |
Note 2 - Significant Accounti_3
Note 2 - Significant Accounting Policies (Details Textual) | 1 Months Ended | 12 Months Ended | |||||||||||||
Jan. 03, 2023 shares | Nov. 08, 2022 | Nov. 07, 2022 | Oct. 27, 2022 | Oct. 26, 2022 shares | Sep. 30, 2022 | Aug. 03, 2022 | Jul. 27, 2022 $ / shares shares | May 18, 2020 shares | Aug. 30, 2022 shares | Dec. 31, 2021 USD ($) | Mar. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) | Aug. 04, 2022 $ / shares shares | Nov. 02, 2021 shares | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 1 | ||||||||||||||
Cash Equivalents, at Carrying Value | $ | $ 0 | $ 0 | |||||||||||||
Share Price Of Final Price Of Share (in shares) | 902.70 | ||||||||||||||
Temporary Equity, Accretion to Redemption Value | $ | $ 2.1 | ||||||||||||||
Percentage of Cumulative Dividends on Preferred Stock | 8% | ||||||||||||||
Prefunded Warrants [Member] | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 401,667 | 42,250 | |||||||||||||
Percentage Of Warrant Exercisable | 20% | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.005 | $ 0.005 | |||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||
Percentage of Cumulative Dividends on Preferred Stock | 8% | ||||||||||||||
TardiMed [Member] | Prefunded Warrants [Member] | |||||||||||||||
Share Price Of Final Price Of Share (in shares) | 11.95 | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 181,083 | 72,435 | |||||||||||||
Percentage Of Warrant Exercisable | 20% | 20% | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.0001 | ||||||||||||||
Percentage of Cash Less Warrant Exercised | 20% | 20% | 20% | ||||||||||||
Stock Issued During Period, Shares, Warrant Exercised (in shares) | 36,110 | 36,166 | 36,196 | ||||||||||||
TardiMed [Member] | Series A Preferred Stock [Member] | |||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,819 | ||||||||||||||
Furniture and Fixtures [Member] | |||||||||||||||
Property, Plant and Equipment, Useful Life (Year) | 7 years | ||||||||||||||
Computer Equipment [Member] | |||||||||||||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | ||||||||||||||
Reverse Stock Split [Member] | |||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 50 | 50 | 12 |
Note 2 - Significant Accounti_4
Note 2 - Significant Accounting Policies - Reconciliation of Diluted Net Income (Loss) (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Net loss | $ (4,061,252) | $ (3,073,394) |
Net (loss) income attributable to common stockholders | $ (4,061,252) | $ (3,073,394) |
Basic and diluted weighted average number of shares outstanding (in shares) | 3,077,993 | 1,272,754 |
Basic and diluted net loss per share attributable to common stockholders (in dollars per share) | $ (1.32) | $ (2.41) |
Note 2 - Significant Accounti_5
Note 2 - Significant Accounting Policies - Schedule of Earnings Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Antidilutive Securities (in shares) | 2,807,978 | 945,960 |
Series A Warrants [Member] | ||
Antidilutive Securities (in shares) | 334,036 | 334,036 |
Bridge Warrants [Member] | ||
Antidilutive Securities (in shares) | 8,275 | 8,275 |
Value Appreciation Rights [Member] | ||
Antidilutive Securities (in shares) | 4,546 | 4,546 |
Options To Purchase Common Stock [Member] | ||
Antidilutive Securities (in shares) | 89,632 | 53,153 |
Series A Preferred Stock [Member] | ||
Antidilutive Securities (in shares) | 0 | 2,337 |
Legacy Stock Options [Member] | ||
Antidilutive Securities (in shares) | 316 | 316 |
Legacy Warrants [Member] | ||
Antidilutive Securities (in shares) | 2,027 | 4,235 |
November 2021 Warrants [Member] | ||
Antidilutive Securities (in shares) | 539,063 | 539,063 |
August 2022 Common Stock Warrants [Member] | ||
Antidilutive Securities (in shares) | 1,309,333 | 0 |
Warrants Issued In October2022 Financing [Member] | ||
Antidilutive Securities (in shares) | 520,000 | 0 |
Restricted Stock Units (RSUs) [Member] | ||
Antidilutive Securities (in shares) | 750 | 0 |
Note 3 - Purchases of Assets (D
Note 3 - Purchases of Assets (Details Textual) | 3 Months Ended | 12 Months Ended | |||||
Apr. 30, 2022 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2022 USD ($) | Jul. 20, 2022 USD ($) | Jun. 30, 2022 USD ($) | Jul. 05, 2019 USD ($) | |
Asset Acquisition, Milestone Payments Payable, Current | $ 1,750,000 | $ 1,750,000 | |||||
Prepaid Expense, Current | 204,443 | 525,532 | |||||
TMB001 License [Member] | |||||||
Milestone Payments Made To Start Trial | $ 2,230,000 | ||||||
Prepaid Expense, Current | 116,000 | ||||||
Acquisition Of Licenses From Patagonia Pharmaceuticals LLC [Member] | TMB001 License [Member] | |||||||
Upfront Fee | 50,000 | ||||||
Cash Milestone Payments Entitled | 27,000,000 | ||||||
Initial Cash Milestone Payments Entitled | 4,000,000 | ||||||
Accrued Milestone Payments | 0 | 0 | $ 4,000,000 | ||||
Asset Acquisition, Number Of Tranches In Which First Milestone Payment is Payable | 2 | ||||||
Asset Acquisition, Milestone Payments Payable, Current | $ 2,250,000 | ||||||
Asset Acquisition, Milestone Payments Payable, Non Current | 1,750,000 | ||||||
Asset Acquisition, Milestone Payments, Additional Payable | 315,000 | ||||||
Asset Acquisition, Milestone Payments, Including Additional Payable | $ 2,065,000 | ||||||
Interest Expense | 62,977 | ||||||
Acquisition Of Licenses From Patagonia Pharmaceuticals LLC [Member] | TMB003 License [Member] | |||||||
Upfront Fee | 20,000 | ||||||
Cash Milestone Payments Entitled | 10,250,000 | ||||||
Initial Cash Milestone Payments Entitled | $ 250,000 | ||||||
Acquisition Of License From Aft Pharmaceuticals Limited [Member] | TMB002 License [Member] | |||||||
Cash Milestone Payments Entitled | $ 25,500,000 | ||||||
Initial Cash Milestone Payments Entitled | $ 1,000,000 | ||||||
Accrued Milestone Payments | $ 0 | $ 0 | |||||
Revenues | $ 300,000 |
Note 4 - Accrued Expense - Accr
Note 4 - Accrued Expense - Accrued Expenses, Net (Details) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Research and development | $ 531,040 | $ 436,128 |
Professional fees | 249,510 | 192,108 |
Personnel expenses | 217,501 | 680,181 |
Accrued interest on Patagonia milestone payable | 182,842 | 119,865 |
Asset Retirement Obligation for former BioPharmX location | 150,000 | 150,000 |
Franchise tax payable | 163,408 | 0 |
Other | 81,928 | 31,253 |
Total | $ 1,576,229 | $ 1,609,535 |
Note 5 - Stockholder's Equity_2
Note 5 - Stockholder's Equity (Details Textual) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||||||||
Apr. 02, 2023 shares | Jan. 04, 2023 shares | Nov. 08, 2022 USD ($) shares | Nov. 07, 2022 | Oct. 27, 2022 | Oct. 26, 2022 shares | Oct. 03, 2022 USD ($) $ / shares shares | Sep. 30, 2022 | Aug. 08, 2022 shares | Aug. 04, 2022 $ / shares shares | Aug. 03, 2022 shares | Jul. 27, 2022 $ / shares shares | Nov. 09, 2021 shares | Nov. 09, 2021 shares | Nov. 02, 2021 USD ($) $ / shares shares | May 18, 2020 USD ($) $ / shares shares | May 12, 2023 shares | Mar. 31, 2023 USD ($) $ / shares shares | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) $ / shares shares | Apr. 30, 2023 shares | Aug. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 1 | ||||||||||||||||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 2,971,439 | 27,347 | 3,007,635 | 2,969,272 | |||||||||||||||||||
Fraction of Shares Issued (in shares) | 0 | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 931,667 | ||||||||||||||||||||||
Percentage of Cumulative Dividends on Preferred Stock | 8% | ||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |||||||||||||||||||||
Non Cash Interest Expenses On Reclassification of Redeemable Preferred Stock | $ | $ 0 | $ 54,252 | |||||||||||||||||||||
Share Price Of Final Price Of Share (in shares) | 902.70 | ||||||||||||||||||||||
TardiMed [Member] | |||||||||||||||||||||||
Class Of Warrant Or Right, Exercised (in shares) | 36,113 | 36,166 | 36,196 | 36,216 | |||||||||||||||||||
Percent of Warrant Becomes Exercised | 20% | 20% | 20% | ||||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ | $ 122,777 | $ 189,595 | |||||||||||||||||||||
TardiMed [Member] | Subsequent Event [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 36,219 | ||||||||||||||||||||||
Class Of Warrant Or Right, Exercised (in shares) | 36,110 | 36,110 | |||||||||||||||||||||
Percent of Warrant Becomes Exercised | 20% | ||||||||||||||||||||||
Prefunded Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 401,667 | 42,250 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 6 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.005 | $ 0.005 | |||||||||||||||||||||
Percentage Of Warrant Exercisable | 20% | ||||||||||||||||||||||
Prefunded Warrants [Member] | TardiMed [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 181,083 | 72,435 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.0001 | ||||||||||||||||||||||
Share Price Of Final Price Of Share (in shares) | 11.95 | ||||||||||||||||||||||
Percentage Of Warrant Exercisable | 20% | 20% | |||||||||||||||||||||
Common Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,333,333 | 468,750 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 5.995 | ||||||||||||||||||||||
November 2021 Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 539,063 | 539,063 | |||||||||||||||||||||
Class of Warrant or Right, Purchase Price Per Warrant (in dollars per share) | $ / shares | $ 31.95 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 35 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||||
Class Of Warrant Or Right, Exercised (in shares) | 0 | 0 | |||||||||||||||||||||
Class of Warrant or Right, Number of Warrants Exercised (in shares) | 0 | 0 | |||||||||||||||||||||
Warrants and Rights Outstanding | $ | $ 8,100,000 | ||||||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ | $ 0 | $ 0 | |||||||||||||||||||||
November 2021 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | ||||||||||||||||||||||
November 2021 Warrants [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 73.1 | ||||||||||||||||||||||
November 2021 Warrants [Member] | Measurement Input, Expected Term [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 5 | ||||||||||||||||||||||
Over-allotment Option Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 70,313 | 70,313 | |||||||||||||||||||||
August 2022 Common Stock Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,333,333 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||||||||
Class Of Warrant Or Right, Exercised (in shares) | 24,000 | ||||||||||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ | $ 0 | $ 4,844,533 | $ 4.9 | ||||||||||||||||||||
August 2022 Common Stock Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | ||||||||||||||||||||||
August 2022 Common Stock Warrants [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 97.67 | ||||||||||||||||||||||
August 2022 Common Stock Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 2.91 | ||||||||||||||||||||||
August 2022 Common Stock Warrants [Member] | Measurement Input, Expected Term [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 5 | ||||||||||||||||||||||
Series One Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 260,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years 6 months | ||||||||||||||||||||||
Series Two Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 260,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years 6 months | ||||||||||||||||||||||
Series B Mirroring Preferred Stock [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 13,000 | ||||||||||||||||||||||
Bridge Loan [Member] | |||||||||||||||||||||||
Debt Instrument, Face Amount | $ | $ 5,000,000 | ||||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 83,733 | ||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 20,000,000 | ||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 17,500,000 | ||||||||||||||||||||||
November 2021 Offering [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 539,063 | 426,500 | |||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 32 | ||||||||||||||||||||||
Over-Allotment Option [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 70,313 | ||||||||||||||||||||||
October 2022 Offerings [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 260,000 | ||||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 1,000,000 | ||||||||||||||||||||||
Proceeds From Issuance Of Common Stock Gross | $ | $ 1,300,000 | ||||||||||||||||||||||
October 2022 Offerings [Member] | Series One Warrants [Member] | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 260,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years 6 months | ||||||||||||||||||||||
Merger Agreement With Timber And Merger Sub [Member] | |||||||||||||||||||||||
Stock Issued During Period, Shares, Acquisitions (in shares) | 27,347 | ||||||||||||||||||||||
Equity Issued in Business Combination, Fair Value Disclosure | $ | $ 8,400,000 | ||||||||||||||||||||||
Equity Issued in Business Combination Fair Value, Price Per Share (in dollars per share) | $ / shares | $ 6.12 | ||||||||||||||||||||||
TardiMed [Member] | Conversion of Common Units into Common Stock [Member] | |||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 180 | ||||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 113,323 | ||||||||||||||||||||||
Patagonia [Member] | Conversion of Common Units into Common Stock [Member] | |||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 20 | ||||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 12,591 | ||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||
Stock Cancelled During Period, Shares (in shares) | 13,000 | ||||||||||||||||||||||
Consideration from Cancel of Stock | $ | $ 0 | ||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |||||||||||||||||||||
Number of Votes Per Share | 10,000,000 | 10,000,000 | |||||||||||||||||||||
Average Minimum Bid Price Per Share (in dollars per share) | $ / shares | $ 0.20 | $ 0.20 | |||||||||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||||||||
Designation of Undesignated Preferred Stock (in shares) | 2,500 | ||||||||||||||||||||||
Percentage of Cumulative Dividends on Preferred Stock | 8% | ||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 1,000 | ||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price Per Share (in dollars per share) | $ / shares | $ 902.70 | ||||||||||||||||||||||
Dividends Payable | $ | $ 129,992 | ||||||||||||||||||||||
Series A Preferred Stock [Member] | TardiMed [Member] | |||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,819 | ||||||||||||||||||||||
Redeemable Series Convertible Preferred Stock [Member] | |||||||||||||||||||||||
Non Cash Interest Expenses On Reclassification of Redeemable Preferred Stock | $ | $ 0 | $ 52,452 | |||||||||||||||||||||
Redeemable Series Convertible Preferred Stock [Member] | TardiMed [Member] | |||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,819 | ||||||||||||||||||||||
Minimum [Member] | November 2021 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.05 | ||||||||||||||||||||||
Maximum [Member] | November 2021 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.08 | ||||||||||||||||||||||
Reverse Stock Split [Member] | |||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 50 | 50 | 12 | ||||||||||||||||||||
Reverse Stock Split [Member] | Minimum [Member] | |||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 25 | ||||||||||||||||||||||
Reverse Stock Split [Member] | Maximum [Member] | |||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 50 |
Note 5 - Stockholder's Equity -
Note 5 - Stockholder's Equity - Schedule of Warrants Outstanding (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |||||||||
Jan. 04, 2023 | Oct. 26, 2022 | Aug. 08, 2022 | Aug. 03, 2022 | Mar. 31, 2023 | Dec. 31, 2022 | Aug. 31, 2022 | Aug. 04, 2022 | Nov. 09, 2021 | Nov. 19, 2020 | May 22, 2020 | |
TardiMed [Member] | |||||||||||
Outstanding, shares underlying warrants (in shares) | 72,435 | 108,651 | |||||||||
Outstanding, weighted average exercise price (in dollars per share) | $ 0.0050 | $ 0.0050 | |||||||||
Outstanding, intrinsic value | $ 122,777 | $ 189,595 | |||||||||
Exercised, shares underlying warrants (in shares) | (36,113) | (36,166) | (36,196) | (36,216) | |||||||
Exercised, weighted average exercise price (in dollars per share) | $ 0.0050 | ||||||||||
Warrants Issued In October2022 Financing [Member] | |||||||||||
Outstanding, weighted average exercise price (in dollars per share) | $ 5.50 | $ 5.50 | |||||||||
Outstanding, weighted average remaining contractual term (Year) | 2 years 6 months | 2 years 6 months | |||||||||
Outstanding, intrinsic value | $ 0 | $ 5,200 | |||||||||
Outstanding, shares underlying warrants (in shares) | 520,000 | 520,000 | |||||||||
Series A Warrants [Member] | |||||||||||
Outstanding, shares underlying warrants (in shares) | 334,306 | 334,306 | |||||||||
Outstanding, weighted average exercise price (in dollars per share) | $ 58 | $ 58 | |||||||||
Outstanding, weighted average remaining contractual term (Year) | 2 years 2 months 12 days | 2 years 4 months 24 days | |||||||||
Outstanding, intrinsic value | $ 0 | $ 0 | |||||||||
Outstanding, shares underlying warrants (in shares) | 334,036 | 403,564 | |||||||||
Warrants Related To Bridge Notes [Member] | |||||||||||
Outstanding, shares underlying warrants (in shares) | 8,275 | 8,275 | |||||||||
Outstanding, weighted average exercise price (in dollars per share) | $ 1 | $ 1 | |||||||||
Outstanding, weighted average remaining contractual term (Year) | 2 years 1 month 6 days | 2 years 4 months 24 days | |||||||||
Outstanding, intrinsic value | $ 5,793 | $ 6,206 | |||||||||
Outstanding, shares underlying warrants (in shares) | 8,275 | 8,275 | 8,275 | ||||||||
November 2021 Warrants [Member] | |||||||||||
Outstanding, shares underlying warrants (in shares) | 539,063 | 539,063 | |||||||||
Outstanding, weighted average exercise price (in dollars per share) | $ 35 | $ 35 | |||||||||
Outstanding, weighted average remaining contractual term (Year) | 3 years 7 months 6 days | 3 years 9 months 18 days | |||||||||
Outstanding, intrinsic value | $ 0 | $ 0 | |||||||||
Exercised, shares underlying warrants (in shares) | 0 | 0 | |||||||||
Outstanding, shares underlying warrants (in shares) | 539,063 | ||||||||||
August 2022 Common Stock Warrants [Member] | |||||||||||
Outstanding, shares underlying warrants (in shares) | 1,309,333 | 1,309,333 | |||||||||
Outstanding, weighted average exercise price (in dollars per share) | $ 6 | $ 6 | |||||||||
Outstanding, weighted average remaining contractual term (Year) | 4 years 4 months 24 days | 4 years 10 months 24 days | |||||||||
Outstanding, intrinsic value | $ 0 | $ 4,844,533 | $ 4.9 | ||||||||
Exercised, shares underlying warrants (in shares) | (24,000) | ||||||||||
Outstanding, shares underlying warrants (in shares) | 1,333,333 |
Note 6 - Equity-Based Compens_3
Note 6 - Equity-Based Compensation (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||
May 18, 2020 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Jan. 01, 2022 | Apr. 20, 2021 | Apr. 19, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | ||||||
Incentive Units [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 4,546 | |||||||
Value Appreciation Rights [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 4,546 | 4,546 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares) | 0 | 1,058 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 0 | 1,587 | ||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 10 | |||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 month 6 days | |||||||
Share-Based Payment Arrangement, Option [Member] | ||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 400 | |||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 3 months 18 days | |||||||
Restricted Stock Units (RSUs) [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | |||||||
Omnibus Equity Incentive Plan2020 [Member] | ||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 19,417 | 144,262 | 93,366 | 41,123 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 3 years | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 42,674 | 50,895 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum | 4% | |||||||
Omnibus Equity Incentive Plan2019 [Member] | Incentive Units [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) | 13,989 |
Note 6 - Equity-Based Compens_4
Note 6 - Equity-Based Compensation - Equity-Based Compensation Expenses (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share based compensation | $ 137,526 | $ 368,282 |
Stock Appreciation Rights (SARs) [Member] | General and Administrative Expense [Member] | ||
Share based compensation | 3,301 | (10,754) |
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member] | ||
Share based compensation | 97,357 | 335,779 |
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member] | ||
Share based compensation | 29,143 | 43,257 |
Restricted Stock Units (RSUs) [Member] | General and Administrative Expense [Member] | ||
Share based compensation | $ 7,725 | $ 0 |
Note 6 - Equity-Based Compens_5
Note 6 - Equity-Based Compensation - Schedule of VARs Outstanding (Details) - Value Appreciation Rights [Member] - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Outstanding (in shares) | 4,546 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.50 | |
Outstanding, intrinsic value | $ 5,455 | $ 5,682 |
Outstanding, weighted average remaining contractual life (Year) | 6 years 3 months 18 days | 6 years 6 months |
Outstanding (in shares) | 4,546 | 4,546 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.50 | $ 0.50 |
Value appreciation right awards vested and exercisable (in shares) | 2,883 | |
Value appreciation right awards vested and exercisable, weighted average exercise price (in dollars per share) | $ 0.50 | |
Value appreciation right awards vested and exercisable, intrinsic value | $ 3,460 | |
Value appreciation right awards vested and exercisable, intrinsic value, weighted average remaining contractual life (Year) | 6 years 3 months 18 days |
Note 6 - Equity-Based Compens_6
Note 6 - Equity-Based Compensation - Summary of Options Outstanding (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Outstanding (in shares) | 89,632 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 37.37 | |
Outstanding, weighted average remaining contractual term (Year) | 8 years 7 months 6 days | 8 years 10 months 24 days |
Outstanding, intrinsic value | $ 216 | $ 306 |
Outstanding (in shares) | 89,632 | 89,632 |
Outstanding, weighted average exercise price (in dollars per share) | $ 37.37 | $ 37.37 |
Exercisable (in shares) | 27,462 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 55.95 | |
Exercisable, weighted average remaining contractual term (Year) | 8 years 3 months 18 days |
Note 6 - Equity-Based Compens_7
Note 6 - Equity-Based Compensation - Legacy Stock Options and Warrants (Details) - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Legacy Stock Options [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 316 | 316 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ 3,623.63 | $ 3,763.55 |
Outstanding, weighted average remaining contractual term (Year) | 1 month 6 days | 4 months 24 days |
Outstanding (in shares) | 316 | 316 |
Legacy BioPharmX options, weighted average exercise price (in dollars per share) | $ 3,623.63 | $ 3,763.55 |
Legacy BioPharmX options, weighted average remaining contractual term (Year) | 1 month 6 days | 4 months 24 days |
Legacy Bio Pharm Warrants [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 2,027 | 2,027 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ 5,250 | $ 5,250 |
Outstanding, weighted average remaining contractual term (Year) | 1 year 7 months 6 days | 1 year 9 months 18 days |
Outstanding (in shares) | 2,027 | 2,027 |
Legacy BioPharmX options, weighted average exercise price (in dollars per share) | $ 5,250 | $ 5,250 |
Legacy BioPharmX options, weighted average remaining contractual term (Year) | 1 year 7 months 6 days | 1 year 9 months 18 days |
Note 6 - Equity-Based Compens_8
Note 6 - Equity-Based Compensation - Summary of Outstanding RSUs (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2023 | Dec. 31, 2022 | |
Outstanding (in shares) | 3,000 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 15.35 | |
Outstanding, weighted average remaining contractual term (Year) | 1 month 6 days | 2 months 12 days |
Outstanding, intrinsic value | $ 0 | $ 0 |
Vested and issued, shares underlying restricted stock units (in shares) | (2,250) | |
Vested and issued, fair value (in dollars per share) | $ 15.35 | |
Unvested, shares underlying restricted stock units (in shares) | 750 | 3,000 |
Outstanding, weighted average exercise price (in dollars per share) | $ 15.35 | $ 15.35 |
Note 7 - Commitments and Cont_3
Note 7 - Commitments and Contingencies (Details Textual) | 3 Months Ended | ||||
Feb. 08, 2023 USD ($) ft² | Mar. 31, 2023 USD ($) | Mar. 31, 2022 USD ($) | Mar. 10, 2021 ft² | Feb. 01, 2020 | |
Sublease Income | $ 0 | $ 106,761 | |||
Office Space at 3 Mountainview Road, Warren, New Jersey [Member] | |||||
Area of Real Estate Property (Square Foot) | ft² | 5,281 | ||||
Lessee Operating Lease Base Rent per Month | $ 8,801.67 | ||||
Lessee, Operating Lease, Term of Contract (Month) | 37 months | ||||
Office Space at 110 Allen Road, Suite 401, Basking Ridge, New Jersey [Member] | |||||
Area of Real Estate Property (Square Foot) | ft² | 3,127 | ||||
Lessee, Operating Lease, Term of Contract (Month) | 24 months | ||||
Security Deposit | 13,000 | ||||
Sublease at BioPharmX Facility in San Jose, California [Member] | |||||
Lessor, Operating Lease, Term of Contract (Year) | 4 years | ||||
Sublease Income | $ 0 |
Note 7 - Commitments and Cont_4
Note 7 - Commitments and Contingencies - Lease Expense (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating leases: | ||
Operating lease cost | $ 99,896 | $ 99,142 |
Variable lease cost | 23,954 | 18,425 |
Operating lease expense | 123,850 | 117,567 |
Lease income - sub lease | 0 | (106,761) |
Net rent expense | $ 123,850 | $ 10,806 |
Note 7 - Commitments and Cont_5
Note 7 - Commitments and Contingencies - Other Information (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating cash flows - operating leases | $ 105,147 | $ 98,448 |
Right-of-use assets obtained in exchange for operating lease liabilities | $ 385,682 | $ 0 |
Weighted-average remaining lease term – operating leases (Year) | 3 years 3 months 18 days | 1 year 7 months 6 days |
Weighted-average discount rate – operating leases | 14.10% | 14.20% |
Note 7 - Commitments and Cont_6
Note 7 - Commitments and Contingencies - Future Minimum Payments (Details) | Mar. 31, 2023 USD ($) |
Remaining Months in Year Ending December 31, 2023 | $ 327,266 |
Year Ended December 31, 2024 | 107,820 |
Year Ended December 31, 2025 | 110,461 |
Year Ended December 31, 2026 | 113,101 |
Year Ended December 31, 2027 | 115,742 |
Thereafter | 19,364 |
Total | 793,754 |
Less: present value discount | (168,324) |
Operating lease liabilities | $ 625,430 |
Note 8 - Related Party Transa_2
Note 8 - Related Party Transactions (Details Textual) - USD ($) | 3 Months Ended | |||
Mar. 04, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Patagonia [Member] | ||||
Investment Owned, Balance, Shares (in shares) | 0 | 0 | ||
Patagonia [Member] | Value Appreciation Rights [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 1,587 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) | 1,058 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period (in shares) | 1,194 | |||
Patagonia [Member] | Value Appreciation Rights [Member] | Zachary Rome [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ 22,528 | |||
TardiMed [Member] | ||||
Investment Owned, Balance, Shares (in shares) | 0 | |||
Management Fee Expense | $ 0 | $ 0 |
Note 9 - Subsequent Events (Det
Note 9 - Subsequent Events (Details Textual) - shares | 1 Months Ended | 3 Months Ended | |||||||
Apr. 15, 2023 | Apr. 02, 2023 | Jan. 04, 2023 | Oct. 26, 2022 | Aug. 03, 2022 | May 12, 2023 | Mar. 31, 2023 | Mar. 31, 2022 | Apr. 30, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | |||||||
Restricted Stock Units (RSUs) [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||||||||
Subsequent Event [Member] | Share-Based Payment Arrangement, Employee [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 131,882 | ||||||||
Subsequent Event [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche One [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 25% | ||||||||
Subsequent Event [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 36 months | ||||||||
Subsequent Event [Member] | Share-Based Payment Arrangement, Nonemployee [Member] | Restricted Stock Units (RSUs) [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 12 months | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 17,627 | ||||||||
Subsequent Event [Member] | Share-Based Payment Arrangement, Nonemployee [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Restricted Stock Units (RSUs) [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 1 month | ||||||||
TardiMed [Member] | |||||||||
Class Of Warrant Or Right, Exercised (in shares) | 36,113 | 36,166 | 36,196 | 36,216 | |||||
TardiMed [Member] | Subsequent Event [Member] | |||||||||
Percentage of Cash Less Warrant Exercised | 20% | ||||||||
Class Of Warrant Or Right, Exercised (in shares) | 36,110 | 36,110 | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 36,219 |